Targeting Insulin and Insulin-Like Growth Factor Pathways in Epithelial Ovarian Cancer

被引：58

作者：

Beauchamp, Marie-Claude ^{[1
,2
]}

Yasmeen, Amber ^{[1
,2
]}

Knafo, Ariane ^{[1
,2
]}

Gotlieb, Walter H. ^{[1
,2
]}

机构：

[1] McGill Univ, Jewish Gen Hosp, Div Gynecol Oncol, Montreal, PQ H3T 1E2, Canada

[2] McGill Univ, Lady Davis Inst Med Res, Segal Canc Ctr, Montreal, PQ H3T 1E2, Canada

来源：

JOURNAL OF ONCOLOGY | 2010年 / 2010卷

关键词：

D O I：

10.1155/2010/257058

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ovarian cancer is the most lethal of all gynecological malignancies, due in part to the diagnosis at an advanced stage caused by the lack of specific signs and symptoms and the absence of reliable tests for screening and early detection. Most patients will respond initially to treatment but about 70% of them will suffer a recurrence. Therefore, new therapeutic modalities are urgently needed to overcome chemoresistance observed in ovarian cancer patients. Evidence accumulates suggesting that the insulin/insulin growth factor (IGF) pathways could act as a good therapeutic target in several cancers, including ovarian cancer. In this paper, we will focus on the role of insulin/IGF in ovarian cancer tumorigenesis and treatment.

引用

收藏

页数：11

相关论文

共 96 条

[1] Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer [J].

Baron-Hay, S ;

Boyle, F ;

Ferrier, A ;

Scott, C .

CLINICAL CANCER RESEARCH, 2004, 10 (05) :1796-1806

[2] Customizing the targeting of IGF-1 receptor [J].

Baserga, Renato .

FUTURE ONCOLOGY, 2009, 5 (01) :43-50

[3] Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities [J].

Baxter, RC .

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2000, 278 (06) :E967-E976

[4] BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide [J].

Beauchamp, Marie-Claude ;

Knafo, Ariane ;

Yasmeen, Amber ;

Carboni, Joan M. ;

Gottardis, Marco M. ;

Pollak, Michael N. ;

Gotlieb, Walter H. .

GYNECOLOGIC ONCOLOGY, 2009, 115 (02) :193-198

[5] IDENTIFICATION OF INSULIN AND INSULIN-LIKE GROWTH-FACTOR-I (IGF I) RECEPTORS IN OVARIAN-CANCER TISSUE [J].

BECK, EP ;

RUSSO, P ;

GLIOZZO, B ;

JAEGER, W ;

PAPA, V ;

WILDT, L ;

PEZZINO, V ;

LANG, N .

GYNECOLOGIC ONCOLOGY, 1994, 53 (02) :196-201

[6] The role of insulin receptor isoforms and hybrid Insulin/IGF-I receptors in human cancer [J].

Belfiore, Antonino .

CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (07) :671-686

[7] IGF and Insulin Receptor Signaling in Breast Cancer [J].

Belfiore, Antonino ;

Frasca, Francesco .

JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2008, 13 (04) :381-406

[8] AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells [J].

Beltran, Pedro J. ;

Mitchell, Petia ;

Chung, Young-A ;

Cajulis, Elaina ;

Lu, John ;

Belmontes, Brian ;

Ho, Joanne ;

Tsai, Mei Mei ;

Zhu, Min ;

Vonderfecht, Steven ;

Baserga, Renato ;

Kendall, Richard ;

Radinsky, Robert ;

Calzone, Frank J. .

MOLECULAR CANCER THERAPEUTICS, 2009, 8 (05) :1095-1105

[9] Increased cancer-related mortality for patients with type 2 diabetes who use sulforrylureas or insulin [J].

Bowker, SL ;

Majumdar, SR ;

Veugelers, P ;

Johnson, JA .

DIABETES CARE, 2006, 29 (02) :254-258

[10] IGF-I in epithelial ovarian cancer and its role in disease progression [J].

Brokaw, Jane ;

Katsaros, Dionyssios ;

Wiley, Andrew ;

Lu, Lingeng ;

Su, Dan ;

Sochirca, Olga ;

de la Longrais, Irene A. Rigault ;

Mayne, Susan ;

Harvey-Risch ;

Yu, Herbert .

GROWTH FACTORS, 2007, 25 (05) :346-354

← 1 2 3 4 5 6 7 8 9 10 →